News
Boehringer Ingelheim and Eli Lilly announced that the European Commission has approved an expanded therapeutic indication for the DPP-4 inhibitor Trajenta to include use in combination with ...
Boehringer Ingelheim and Eli Lilly announced that the European Commission has approved an expanded therapeutic indication for the DPP-4 inhibitor Trajenta to include use in combination with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback